Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

  1. Non-insulin pharmacological therapies for treating type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exenatide: pharmacokinetics, clinical use, and future directions

    Research output: Contribution to journalReviewResearchpeer-review

  3. Management of cardiovascular disease in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction - a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Renoprotection with Semaglutide and Liraglutide: Direct or Indirect Effects?

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Effects of dapagliflozin, metformin or exercise on glucose metabolism and glycaemic variability in individuals with prediabetes: The PRE-D trial

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

INTRODUCTION: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type 2 diabetes (T2D). Areas covered: This review provides an overview of the safety and efficacy of exenatide QW for the treatment of T2D and evaluates the benefit-risk ratio compared to other available long-acting GLP-1RAs. In addition, the authors provide an outline of the novel formulations and delivery methods of exenatide. Expert opinion: Exenatide QW is an efficacious and safe treatment for T2D. However, head-to-head trials have demonstrated exenatide QW to be inferior to liraglutide and semaglutide with respect to effects on fasting plasma glucose, glycated hemoglobin A1c, and bodyweight. In addition, exenatide QW appears inferior to liraglutide and semaglutide in terms of cardiovascular risk reduction. Currently, the overall risk-benefit profiles for the range of GLP-1RAs point to liraglutide and semaglutide as first-choice for the management of T2D, which has been confirmed by a recently published consensus report on the treatment of T2D from the American Diabetes Association and the European Association for the Study of Diabetes. The pricing of exenatide QW will most likely be a key determinant for its place in the future management of T2D.

Original languageEnglish
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number5
Pages (from-to)501-510
Number of pages10
ISSN1465-6566
DOIs
Publication statusPublished - 2019

    Research areas

  • cardiovascular adverse events, Exenatide extended-release, exenatide QW, glucagon-like peptide 1, glucagon-like peptide 1 receptor agonist, glycaemic control, type 2 diabetes, Body Weight, Exenatide/therapeutic use, Humans, Animals, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptides/therapeutic use, Glucagon-Like Peptide-1 Receptor/agonists, Glycated Hemoglobin A/metabolism, Hypoglycemic Agents/adverse effects, Liraglutide/therapeutic use

ID: 56500407